Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 210-112-3 | CAS number: 606-28-0
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics
- Adequacy of study:
- other information
Reference
Description of key information
There are no specific studies available with respect to toxicokinetics, metabolism and distribution of the substance.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
There are no studies available for the determination of toxicokinetics or dermal absorption of the substance.
Methyl-2-benzoylbenzoate is a powder with a molecular weight of 240.25 g/mol, a very low vapour pressure of 9.7 x 10-6 Pa at 20 °C, and a log Kow of 2.8. The water solubility is ca. 117 mg/l. Due to its very low vapour pressure, exposure to vapour is highly unlikely. The combination of a molecular weight below 500 g/mol and moderate lipophilicity (log Kow between 1 and 4) favours oral as well as dermal uptake. From the log Kow below 4 it is expected, that the substance does not bioaccumulate.
Acute dermal and oral toxicity tests did not show signs of systemic toxicity. In a repeated dose toxicity/screening reproduction toxicity study via the oral route (OECD 422) effects on liver and kidneys were observed. Test substance related differences were found in liver and kidney weights at the high dose (500 mg/kg bw/day) in both sexes and at the mid dose (125 mg/kg bw/day) in males, in correlation with histopathological changes (hepatocellular hypertrophy of the liver, and degeneration in the cortical/corticomedullary tubules of the kidney). The effects on liver and kidney observed in this study suggest good oral uptake, metabolism in the liver and excretion via urine.
Methyl-2-benzoylbenzoate belongs to the class of aromatic (benzyl) esters. Benzyl esters are known to be rapidly absorbed through the gastrointestinal tract, metabolized primarily in the liver, and excreted in the urine. Hydrolysis of the ester-bond occurs by non-specific carboxylesterases to yield benzyl alcohol that is subsequently oxidized to benzoic acid as a stable metabolite or end-product, and acetic acid. Benzoic acid derivatives are efficiently excreted primarily in the urine, either unchanged or as conjugates of benzoic acid derivatives
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
